There is a particular kind of quiet that settles over me when I read a scientific paper and notice who is missing from it. This week I kept returning to a single absence. A little girl, six years old, whose parents spent a fortune trying to rewrite the letters of her brain, and who did not survive the week. The work went on. A journal published the science that grew from the same soil, and her name is nowhere in it. She became a data point that got tidied out of the record.
I sat with that longer than I meant to. We talk a lot in this line of work about rigor and endpoints and statistical power, and those things matter. But a study is also a story about real people who trusted someone in a white coat, and when the ending is inconvenient the temptation to let it fall out of the frame is very human and very dangerous.
So that is the thread I want you carrying into your Sunday. Not fear of the science, which can be extraordinary, but a stubborn insistence that the people in it get counted. The evidence only means something if we refuse to look away from the parts that hurt.
Autoimmune & Inflammation
A Chinese Bark Compound Reached the Black-Box Arthritis Drugs’ Pathway From Upstream, in Rats
In rats, a compound from the bark of the Amur cork tree reached the same JAK-STAT pathway as Xeljanz and its black-box cousins, but by rebalancing the cell’s fat metabolism instead of blocking the pathway directly.
Investigations
A Gene-Editing Trial Killed a 6-Year-Old. Nature Published the Science and Left Her Out of the Record.
Her parents paid $860,000 to base-edit their daughter’s brain. She died of an immune reaction within a week, the trial’s fatal outcome was never disclosed, and the Nature paper built on the same work never names her.
Cancer
The Evolutionary Fix for Drug Resistance Works Best on a Tumor Too Small to Find
City St George’s mathematicians say hitting a tumor at its weakest moment can drive it extinct. Their own model clears 95 percent only below 7 million cells, far smaller than any tumor a scan can find.
Metabolic & Weight
Orforglipron Reaches Deep Into the Brain’s Reward Circuit and Turns the Dopamine Down
In mice engineered with human GLP-1 receptors, the new oral pills reached the central amygdala, a deep reward hub, and thinned the dopamine payoff of eating for pleasure. The government’s addiction institute is already watching.
The GLP-1s That Barely Move the Scale Don’t Cause Hair Loss, and That’s the Clue Everyone Missed
Women on semaglutide shed hair at about twice the rate of men, and the weakest GLP-1s show almost no signal, which points the cause away from the follicle and straight at how fast the weight comes off.
Brain & Aging
The Sweeteners Sold to Diabetics as the Safe Swap Tracked With Faster Brain Aging
Brazilian researchers followed 12,772 adults for eight years. The ones consuming the most artificial sweeteners, about a diet soda’s worth a day, showed cognitive decline equal to 1.6 extra years of brain aging, and diabetics fared worst.
Nutrition & Food
Pepsi Paid $1.95 Billion for Poppi, in a Category That Averages as Much Sugar as Fiber
UNC researchers read the labels on 108 prebiotic sodas and found roughly 5 grams of fiber, 5 grams of sugar, and, in most cans, a non-nutritive sweetener. Poppi agreed to an $8.9 million settlement over its gut-health claims; months later Pepsi paid $1.95 billion for it.
The FDA Revoked Two Petroleum Dyes That Industry Abandoned Before Most Americans Were Born
Orange B was last certified in 1978. Citrus Red No. 2 has painted Florida oranges since 1959. The six petroleum dyes actually in the food supply remain on a voluntary timeline no manufacturer has publicly signed.